Resolution criteria

This market will resolve to "Yes" if a treatment enabling adult human tooth regrowth becomes commercially available in any country by December 31, 2035. "Commercially available" is defined as the treatment being offered to the general public through licensed dental practitioners or medical facilities. Verification will be based on official announcements from regulatory bodies, reputable medical institutions, or major news outlets.

Background

Research into adult tooth regeneration has progressed significantly. In 2023, Japanese scientists developed a drug targeting the USAG-1 protein, which inhibits tooth growth. Animal trials demonstrated successful tooth regrowth without significant side effects. Human clinical trials began in July 2024, with the aim of making the treatment available by 2030. (mainichi.jp) Additionally, in April 2025, UK researchers successfully grew human teeth in a lab, offering a potential alternative to dental implants and fillings. (en.wikipedia.org)

Considerations

While current projections suggest commercial availability by 2030, unforeseen challenges in clinical trials, regulatory approvals, or manufacturing could delay this timeline. Additionally, the initial availability may be limited to specific regions or patient groups, such as those with congenital tooth deficiencies, before broader public access is achieved.